Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial

 April 22, 2026

BioPharma Dive

A program that got caught up in HHS decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.

Clinical DataInfectious DiseaseRead full story

Post navigation

Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients →

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com